Participant Age Range
18 years and older
“A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of CSL112 in Subjects with Acute Coronary Syndrome”
Acute coronary syndrome is a life-threatening condition, which most commonly occurs when an atherosclerotic plaque ruptures or erodes, leading to thrombus formation within a coronary artery. A thrombus within a coronary artery can result in unstable angina, a myocardial infarction (MI) (heart attack), or sudden death. Even after recovery from an acute episode of ACS, patients continue to be at heightened risk. The short-term morbidity and mortality associated with both the index coronary event and recurrent CV events can be as high as 20% per year. Despite advances in therapeutic strategies for ACS, patients remain at heightened risk for recurrent ischemic events, particularly in the immediate weeks to months following the event. Consequently, effective and safe therapies that provide clinically relevant reductions in recurrent CV events beyond current secondary prophylaxis are needed for patients with ACS.